{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-093550","form_type":"8-K","ticker":"ESLA","cik":"0001844417","company_name":"Estrella Immunopharma, Inc.","filed_at":"2021-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.096164+00:00","generated_at":"2026-06-30T04:36:52.240293+00:00","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TradeUP Acquisition Corp. prices $40M IPO; 4M units at $10 each","bullets":["IPO of 4,000,000 units at $10.00/unit, gross proceeds of $40 million; over-allotment option of 600,000 units available.","Private placement of 295,000 shares to founders at $10/share, raising $2.95 million concurrent with IPO closing.","Net proceeds of $40.8 million ($40M IPO + $0.8M private placement) placed in trust account for business combination.","Board classified: Weston Twigg (Class I, 2022), Tao Jiang & James Long (Class II, 2023), Jianwei Li & Weiguang Yang (Class III, 2024).","Units listed on Nasdaq under UPTDU starting July 15; common stock (UPTD) and warrants (UPTDW) will trade separately later."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-093550","json":"https://secwatch.observer/filing/0001104659-21-093550.json","markdown":"https://secwatch.observer/filing/0001104659-21-093550.md","text":"https://secwatch.observer/filing/0001104659-21-093550.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1844417/000110465921093550/0001104659-21-093550-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1844417/000110465921093550/tm2122516d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T04:36:52.240293+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"067954a10a","claim":"James Long was appointed as Director at Estrella Immunopharma, Inc..","evidence_excerpt":"Effective July 14, 2021, in connection with the effectiveness of the Registration Statement, Weston Twigg, Tao Jiang and James Long became directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1844417/000110465921093550/0001104659-21-093550-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"became director"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"1f5b9271f2","claim":"Weston Twigg was appointed as Director at Estrella Immunopharma, Inc..","evidence_excerpt":"Effective July 14, 2021, in connection with the effectiveness of the Registration Statement, Weston Twigg, Tao Jiang and James Long became directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1844417/000110465921093550/0001104659-21-093550-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"became director"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a419d74faf","claim":"Tao Jiang was appointed as Director at Estrella Immunopharma, Inc..","evidence_excerpt":"Effective July 14, 2021, in connection with the effectiveness of the Registration Statement, Weston Twigg, Tao Jiang and James Long became directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1844417/000110465921093550/0001104659-21-093550-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"became director"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}